Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Nantes
Clinical trial register · France

Clinical Trials in Nantes, 2026

Every study on the ClinicalTrials.gov registry that lists a site in France and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 9698 matching records held by the registry are in this view. Synced 23 Oct 2026, 03:20 UTC
9698
Studies in scope
all four open statuses
6023
Recruiting now
open to new participants
1034
Lead sponsors
across recruiting studies
Top sites
Paris 31 Lille 23 Nantes 17 Marseille 15 Toulouse 15
Narrow the registerReset
Recruitment status
Phase
Site location
Paris31 Lille23 Nantes17 Marseille15 Toulouse15
All 73 locations
Target enrolment
to

Trials with a site in Nantes

17 of 9698 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in France
Start
Recruiting
Sanofi
Phase 3
300
Nantes, Toulouse
2026-05-12
Recruiting
Sanofi
Phase 2/3
526
Bordeaux, Nantes, Paris, Toulouse, Tours
2026-03-13
Recruiting
Sanofi
Phase 3
751
Amiens, Besançon, Créteil, La Tronche, Lille, Marseille, Nantes, Nice
2026-01-16
Recruiting
Sanofi
Phase 2
144
Lille, Nantes, Paris, Rouen
2025-12-29
Recruiting
Sanofi
Phase 3
980
Amiens, Saint-Etienne, Besançon, Créteil, La Tronche, Lille, Marseille, Nantes
2025-10-01
Active, closed
Sanofi
Phase 3
216
Bordeaux, Marseille, Nantes, Poitiers, Pontoise, Toulouse
2025-02-06
Recruiting
Sanofi
Phase 1
87
Lille, Nantes
2024-10-30
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Besançon, Bron, Clermont-Ferrand, Gonesse, Lille, Montpellier, Nancy, Nantes
2024-04-16
Active, closed
Sanofi
Phase 3
260
Marseille, Nantes, Paris, Pessac, Pierre-Bénite, Rennes, Vandœuvre-lès-Nancy
2024-01-23
Active, closed
Sanofi
Observational
150
Nantes
2023-10-20
Active, closed
Sanofi
Phase 2
999
Créteil, Lille, Marseille, Nantes, Paris, Pierre-Bénite, Toulouse
2023-04-03
Active, closed
Sanofi
Phase 2
187
Marseille, Nantes, Neuilly-sur-Seine, Vandœuvre-lès-Nancy
2022-11-25
Active, closed
Sanofi
Phase 3
531
Nantes, Paris, Poitiers, Saint-Priest-en-Jarez, Toulouse, Tours
2022-06-23
Recruiting
Sanofi
Phase 1/2
258
Lille, Nantes, Paris
2021-01-25
Active, closed
Sanofi
Observational
1,860
Argenteuil, Bordeaux, Lille, Marseille, Martigues, Nantes, Paris, Toulouse
2019-08-15
Active, closed
Sanofi
Phase 3
475
Bayonne, Caen, Dijon, La Roche-sur-Yon, Lille, Nantes, Paris, Pessac
2017-12-07
Rows per page Showing 1–17 of 17
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a French investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 October 2026. https://priyalifescience.com/clinical-trials-france/city/nantes

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in France and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,698 studies in total at the last sync on 23 Oct 2026, 03:20 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 17 of those studies with a site in Nantes that also match the filters currently applied.

How many clinical trials are recruiting in Nantes?

7 of the 17 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:20 UTC sync. A further 0 have not yet opened recruitment, 9 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nantes), 17 studies
PhaseStudiesRecruitingShare
Phase 38347.1%
Phase 24123.5%
Observational2011.8%
Phase 1115.9%
Phase 1/2115.9%
Phase 2/3115.9%

Most active sponsors

Lead sponsors with the most studies (Nantes)
Lead sponsorStudiesRecruiting
Sanofi177
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.